Two-year efficacy and safety of subcutaneous tocilizumab in combination with disease-modifying antirheumatic drugs including escalation to weekly dosing in rheumatoid arthritis

Journal of Rheumatology

Volumn 45, Issue 4, 2018, Pages 456-464

  Kivitz, Alan ^a,l,m   Olech, Ewa ^b,m   Borofsky, Michael A ^c,m   Zazueta, Beatriz ^d,m   Navarro Sarabia, Federico ^e,m   Radominski, Sebastião C ^f,m   Merrill, Joan T ^g,m   Pacheco Tena, Cesar ^h,m   Pei, Jinglan ^i,m   Nasmyth Miller, Clare ^j,m   Pope, Janet E ^k,m  

^a Altoona Center for Clinical Research   (United States)

^b University of Nevada School of Medicine   (United States)

^c Clinical Research Center of Reading   (United States)

^d Centro de Investigacion en Enfermedades Reumaticas   (Argentina)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^g OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^h UNIVERSIDAD AUTÓNOMA DE CHIHUAHUA   (Mexico)

ⁱ GENENTECH INC   (United States)

^j Roche Pharmaceuticals   (United States)

^k WESTERN UNIVERSITY   (United States)

^l Altoona Arthritis and Osteoporosis Center   (United States)

^m UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Biological therapy; Clinical trial; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; TOCILIZUMAB; TRIACYLGLYCEROL; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

AMERICAN COLLEGE OF RHEUMATOLOGY 20; AMERICAN COLLEGE OF RHEUMATOLOGY 50; AMERICAN COLLEGE OF RHEUMATOLOGY 70; ARTICLE; BACTERIAL ARTHRITIS; BLEEDING; CELLULITIS; CHOLESTEROL BLOOD LEVEL; COCCIDIOIDOMYCOSIS; CONTROLLED STUDY; DAS28; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEMALE; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART INFARCTION; HUMAN; HYPERSENSITIVITY; HYPERTRANSAMINASEMIA; HYPOTENSION; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; LOWER RESPIRATORY TRACT INFECTION; LUDWIG ANGINA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE ASSESSMENT; NEUTROPENIA; OPEN STUDY; OPPORTUNISTIC INFECTION; OSTEOMYELITIS; OVARY CANCER; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; REMISSION; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; THYROID TUMOR; VIRUS PNEUMONIA; ADULT; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG TOLERANCE; FOLLOW UP; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFECTIONS; INJECTION SITE REACTION; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85044762326     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.161539     Document Type: Article

References (13)

1. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
2. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
3. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
4. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
5. Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69-74.
6. Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res 2014;66:1653-61.
7. Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res 2014;66:344-54.
8. Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis 2016;75:68-74.
9. Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, et al. Longterm safety and efficacy of subcutaneous tocilizumab monotherapy: results from the 2-year open-label extension of the MUSASHI Study. J Rheumatol 2015;42:799-809.
10. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-263.
11. Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010;32:1597-609.
12. Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gomez-Reino J, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 2013;40:768-80.
13. Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina AR, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res 2013;65:94-100.